Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson’s disease
Qiao Chen, Qian Zhang, Qingling Jiang, et al.
Journal of Neuroinflammation (2018) Vol. 15, Iss. 1
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease
Shuo Wang, Yu‐He Yuan, Nai‐Hong Chen, et al.
International Immunopharmacology (2018) Vol. 67, pp. 458-464
Closed Access | Times Cited: 368
Progress towards therapies for disease modification in Parkinson's disease
Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 7, pp. 559-572
Open Access | Times Cited: 239
Targeting the Microglial NLRP3 Inflammasome and Its Role in Parkinson's Disease
Md. Ezazul Haque, Mahbuba Akther, Md. Jakaria, et al.
Movement Disorders (2019) Vol. 35, Iss. 1, pp. 20-33
Closed Access | Times Cited: 203
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
Zheng Fan, Yuting Pan, Zhiyuan Zhang, et al.
Journal of Neuroinflammation (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 168
Inflammasomes in neurological disorders — mechanisms and therapeutic potential
Kishore Aravind Ravichandran, Michael T. Heneka
Nature Reviews Neurology (2024) Vol. 20, Iss. 2, pp. 67-83
Closed Access | Times Cited: 34
Neuroprotective effects of anthocyanins and its major component cyanidin-3-O-glucoside (C3G) in the central nervous system: An outlined review
Jinlin Zhang, Jingjing Wu, Fengguo Liu, et al.
European Journal of Pharmacology (2019) Vol. 858, pp. 172500-172500
Closed Access | Times Cited: 111
A review for the neuroprotective effects of andrographolide in the central nervous system
Jiashu Lu, Yao‐Ying Ma, Jingjing Wu, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 117, pp. 109078-109078
Open Access | Times Cited: 106
miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson’s disease
Yongbo Hu, Yongfang Zhang, Hao Wang, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 8
Open Access | Times Cited: 92
Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model
Cong Yang, Yousheng Mo, Erjin Xu, et al.
International Immunopharmacology (2019) Vol. 75, pp. 105651-105651
Closed Access | Times Cited: 80
NLRP3 inflammasome in neurodegenerative disease
Faith L. Anderson, Karl Biggs, Brynn E. Rankin, et al.
Translational research (2022) Vol. 252, pp. 21-33
Open Access | Times Cited: 67
SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close
Gaber El‐Saber Batiha, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Inflammopharmacology (2022) Vol. 31, Iss. 1, pp. 37-56
Open Access | Times Cited: 67
Andrographolide, a natural anti-inflammatory agent: An Update
Xiaohong Li, Weichen Yuan, Jibiao Wu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 56
Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics
Yueran Cui, Haiyang Yu, Zhongqi Bu, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 41
Parkinson’s Disease Risk and Hyperhomocysteinemia: The Possible Link
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Yaser Hosny Ali Elewa, et al.
Cellular and Molecular Neurobiology (2023) Vol. 43, Iss. 6, pp. 2743-2759
Open Access | Times Cited: 36
NF‐κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 13, pp. 1775-1789
Open Access | Times Cited: 32
Role of Brain Liver X Receptor in Parkinson’s Disease: Hidden Treasure and Emerging Opportunities
Saud A. Alnaaim, Hayder M. Al‐kuraishy, Αθανάσιος Αλεξίου, et al.
Molecular Neurobiology (2023) Vol. 61, Iss. 1, pp. 341-357
Open Access | Times Cited: 27
Neuropharmacological insights into Gardenia jasminoides Ellis: Harnessing therapeutic potential for central nervous system disorders
Ziyu Hou, Le Sun, Zheyu Jiang, et al.
Phytomedicine (2024) Vol. 125, pp. 155374-155374
Closed Access | Times Cited: 9
NLRP3 inflammasome in health and disease (Review)
Haoran Wang, Li Ma, Weiran Su, et al.
International Journal of Molecular Medicine (2025) Vol. 55, Iss. 3
Closed Access | Times Cited: 1
TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson’s disease
Qian-hang Shao, Ying Chen, Fangfang Li, et al.
Acta Pharmacologica Sinica (2019) Vol. 40, Iss. 12, pp. 1503-1512
Open Access | Times Cited: 66
Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?
Marie‐Thérèse Armentero, Silvia Cerri, Fabio Blandini
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 61
Key Mechanisms and Potential Targets of the NLRP3 Inflammasome in Neurodegenerative Diseases
Yadi Guan, Fang Han
Frontiers in Integrative Neuroscience (2020) Vol. 14
Open Access | Times Cited: 58
Overexpression of MicroRNA-9a-5p Ameliorates NLRP1 Inflammasome-mediated Ischemic Injury in Rats Following Ischemic Stroke
Yuze Cao, Huixue Zhang, Xiaoyu Lu, et al.
Neuroscience (2020) Vol. 444, pp. 106-117
Closed Access | Times Cited: 50
Opposing functions of β-arrestin 1 and 2 in Parkinson’s disease via microglia inflammation and Nprl3
Yinquan Fang, Qingling Jiang, Shanshan Li, et al.
Cell Death and Differentiation (2021) Vol. 28, Iss. 6, pp. 1822-1836
Open Access | Times Cited: 43
A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease
Shuxuan Huang, Zhi Chen, Binglin Fan, et al.
Journal of Neuroimmunology (2021) Vol. 354, pp. 577543-577543
Closed Access | Times Cited: 42
The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases
Ya-Shuo Feng, Zixuan Tan, Linyu Wu, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111428-111428
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top